Takeda Drug Shows Ability To Reduce Tumor Growth Rate
This article was originally published in PharmAsia News
Executive Summary
A drug of Takeda Pharmaceuticals has demonstrated effectiveness in reducing the rate of growth of tumors, at least in mice. Takeda, which acquired the MLN4924 when it bought Millennium Pharmaceuticals, has begun human clinical trials as a result of the findings. The new drug, although similar to Takeda's Velcade (bortezomib) for treating blood cancer, differs in that it attacks a different enzyme that regulates the proteins that cancer cells rely on to grow. The new version blocks the process that regulates how some proteins are broken down. (Click here for more